AI in Care: IntelliGen’s AI 3D medical imaging platform is being tested at Taiwan’s MOHW data center, aiming to roll out to all 29 medical centers by 2028 for faster, color 3D organ modeling from CT/MRI. NHI Updates: Taiwan’s MOHW expands National Health Insurance coverage for several rare-disease, cardiovascular, blood disorder and cancer drugs from Oct. 1, including Pembrolizumab and CAR-T Yescarta (with clinical eligibility checks). Drug Policy & HIV Prevention: A local study cited by Taiwan’s CDC chief says methadone maintenance and needle-and-syringe programs are highly cost-effective at reducing HIV transmission among people who inject drugs, fueling debate in Taipei’s mayoral race. Clinical Pipeline Moves: Harrow closed its TYRVAYA nasal spray acquisition (dry eye disease) and Energenesis signed an MOU with Yoo Young Pharm to develop ENERGI-F703DFU for diabetic foot ulcers in Korea; HanchorBio also got U.S. FDA IND clearance for HCB303, a trispecific immunotherapy. Public Health Safety: PDEA warns against “zombie vapes” containing etomidate, stressing serious risks when used outside medical supervision. Wellness Consumer Protection: Singapore’s CASE reports prepaid fitness losses jumping to nearly S$6.7m in 2026, urging mandatory safeguards after gym closures left consumers out of pocket.